CELLERATION RECEIVES $20.6 MILLION IN SERIES C FUNDING

Celleration, Inc., an early stage operating company, the developer of a non-contact ultrasound therapy treatment for chronic and hard to heal wounds, announced today it has closed $20.6 million in Series C financing. Jeffries Broadview advised the Company and served as the placement agent for this transaction. New investors include Triathlon Medical Ventures and New Science Ventures, which co-led the round, with Baird Venture Partners, CID Capital and Seneca Health Partners following. Follow-on investors included Affinity Ventures, Upper Lake Growth Capital, Prism, Venture Investors and AAVIN Equity Partners.
American Venture Magazine